USARx offers multiple ways to purchase this medication. Choose the Best option for you!
NoIn general, Medicare plans do not cover this drug. This drug will likely be quite expensive and you may want to consider using a USARx discount instead of Medicare to find the best price for this prescription.
It depends. Which coverage stage are you in? Click on a tab below…
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your novolog flexpen prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about insulin aspart. Some of the dosage forms listed on this page may not apply to the brand name Novolog.
Common side effects of Novolog include: hypoglycemia. See below for a comprehensive list of adverse effects.
Applies to insulin aspart: solution
Along with its needed effects, insulin aspart (the active ingredient contained in Novolog) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking insulin aspart:
Some side effects of insulin aspart may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to insulin aspart: injectable solution, subcutaneous solution
Adverse reactions observed have included hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.
Hypersensitivity side effects have included both local and systemic reactions. Anaphylaxis has been reported. Local reactions have presented as erythema, local edema, and pruritus at the injection site. Most minor reactions to insulin at the injection site resolve in a few days to a few weeks.
Generalized allergy to insulin may present as a whole body rash, dyspnea, wheezing, hypotension, tachycardia, or diaphoresis. In clinical trials, allergic reactions were reported in 0.7% (10/1394) patients receiving insulin aspart (the active ingredient contained in Novolog)
Clinical trials with Fiasp(R) reported generalized hypersensitivity reactions at 0.2% (comparator 0.1%). Anaphylactic reactions were not reported. Allergic skin manifestations were reported at 1.5% (comparator 1.4%) and included eczema, rash, pruritic rash, urticaria, and dermatitis.
Very rare (less than 0.01%): Anaphylaxis
Common (1% to 10%): Allergic skin manifestations
Frequency not reported: Allergic reactions
Very common (10% or more): Hypoglycemia
Frequency not reported: Weight gain
Weight gain has been reported with insulin therapy and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.
Common (1% to 10%): Chest pain
Uncommon (0.1% to 1%): Peripheral edema
Insulin may cause sodium retention and edema, especially as metabolic control is improving.
Long-term use of insulin may cause lipodystrophy at the site of repeated injection. Lipodystrophy includes lipohypertrophy, a thickening of adipose tissue, and lipoatrophy, thinning of adipose tissue.
Common (1% to 10%): Skin disorder
Uncommon (0.1% to 1%): Urticaria, rash
Frequency not reported: Lipodystrophy including lipohypertrophy and lipoatrophy
Common (1% to 10%): Onychomycosis
Frequency not reported: Anti-insulin antibody titers
The clinical significance of the development of these antibody titers is unknown.
Uncommon (0.1% to 1%): Refraction disorder, worsening of diabetic retinopathy
Rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder and worsening of diabetic retinopathy. However, long-term glycemic control decreases the risk of diabetic retinopathy.
Rapid improvement in glucose control has been associated with a transitory, reversible acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk.
Very common (10% or more): Headache (up to 12%)
Common (1% to 10%): Hyporeflexia, sensory disturbance
Rare (less than 0.1%): Painful peripheral neuropathy
Common (1% to 10%): Nausea, diarrhea, abdominal pain
Common (1% to 10%): Urinary tract infection
Common (1% to 10%): Back pain
Very common (10% or more): Nasopharyngitis (23%)
Common (1% to 10%): Upper respiratory infection
June 26, 2020
June 25, 2020
June 27, 2020
July 10, 2020
July 9, 2020
July 1, 2020